ARGOS THERAPEUTICS INC·4

Sep 20, 8:36 AM ET

ARGOS THERAPEUTICS INC 4

4 · ARGOS THERAPEUTICS INC · Filed Sep 20, 2016

Insider Transaction Report

Form 4
Period: 2016-09-19
Transactions
  • Purchase

    Common Stock

    2016-09-15$4.76/sh+15,880$75,58913,041,946 total(indirect: See footnote)
  • Purchase

    Common Stock

    2016-09-16$4.78/sh+36,632$175,10113,078,578 total(indirect: See footnote)
Footnotes (3)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.73 to $4.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  • [F2]Pharmstandard International S.A. is a wholly owned subsidiary of Public Joint Stock Company Pharmstandard. As the parent entity, Public Joint Stock Company Pharmstandard has voting power over the shares of the Issuer held by Pharmstandard International S.A.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.76 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT